Form 4 Organogenesis Holdings For: May 14 Filed by: Dean Thompson
FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person
*
(Street)
|
2. Issuer Name
and
Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 05/14/2021 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check
Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Class A common stock | 05/14/2021 | J | 21,154,526 (2) (3) | D | $ 0 (2) | 7,721,298 (3) | I | See Notes (1) (6) (7) | ||
Class A common stock | 95,384 (4) | I | See notes (4) (6) (7) | |||||||
Class A common stock | 71,538 (5) | I | See notes (5) (6) (7) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
See Exhibit 99.1 for Signatures incorporated herein by reference | 05/18/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 99.1
Joint Filer Information
Name of Joint Filer:
|
Avista Acquisition Corp.
|
Address of Joint Filer:
|
65 East 55th Street
|
18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required to be Reported (Month/Day/Year):
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Acquisition Corp.
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Attorney-in-Fact
|
|
5/18/2021
|
|
Date
|
1
Joint Filer Information
Name of Joint Filer:
|
Avista Acquisition, LLC
|
Address of Joint Filer:
|
65 East 55th Street
|
18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required to be Reported (Month/Day/Year):
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Acquisition, LLC
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Attorney-in-Fact
|
|
5/18/2021
|
|
Date
|
2
Joint Filer Information
Name of Joint Filer:
|
Avista Capital Partners IV, L.P.
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Capital Partners IV, L.P.
|
|
By: Avista Capital Partners IV GP, L.P.
|
|
By: Avista Capital Managing Member IV, LLC, its general partner
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Authorized Signatory
|
|
5/18/2021
|
|
Date
|
3
Joint Filer Information
Name of Joint Filer:
|
Avista Capital Partners (Offshore) IV, L.P.
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Capital Partners (Offshore) IV, L.P.
|
|
By: Avista Capital Partners IV GP, L.P.
|
|
By: Avista Capital Managing Member IV, LLC, its general partner
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Authorized Signatory
|
|
5/18/2021
|
|
Date
|
4
Joint Filer Information
Name of Joint Filer:
|
Avista Capital Partners IV GP, L.P.
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Capital Partners IV GP, L.P.
|
|
By: Avista Capital Managing Member IV, LLC, its general partner
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Authorized Signatory
|
|
5/18/2021
|
|
Date
|
5
Joint Filer Information
Name of Joint Filer:
|
Avista Capital Managing Member IV, LLC
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
Avista Capital Managing Member IV, LLC
|
|
/s/ Benjamin Silbert | |
Name: Benjamin Silbert
|
|
Title: Authorized Signatory
|
|
5/18/2021
|
|
Date
|
6
Name of Joint Filer:
|
Thompson Dean
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
/s/ Thompson Dean
|
|
Benjamin Silbert, as attorney-in-fact for
|
|
Thompson Dean
|
|
5/18/2021
|
|
Date
|
7
Name of Joint Filer:
|
David Burgstahler
|
Address of Joint Filer:
|
c/o Avista Capital Partners
|
65 East 55th Street, 18th Floor
|
|
New York, NY 10022
|
|
Relationship of Joint Filer to Issuer:
|
10% Owner
|
Director
|
|
Issuer Name and Ticker or Trading Symbol:
|
Organogenesis Holdings Inc. [ORGO]
|
Date of Earliest Transaction Required To be Reported:
|
5/14/2021
|
Designated Filer:
|
Avista Capital Managing Member IV, LLC
|
Signature:
/s/ David Burgstahler
|
|
Benjamin Silbert, as attorney-in-fact for
|
|
David Burgstahler
|
|
5/18/2021
|
|
Date
|
8
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RUM Reports Annual Financial Results with Increased Net Comprehensive Income for the Year Ended December 31, 2023
- Robbins LLP Reminds IRobot Corporation Shareholders of the Pending May 7, 2024 Lead Plaintiff Deadline
- NorthWestern Reports First Quarter 2024 Financial Results
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!